JP2021500861A5 - - Google Patents

Download PDF

Info

Publication number
JP2021500861A5
JP2021500861A5 JP2020517377A JP2020517377A JP2021500861A5 JP 2021500861 A5 JP2021500861 A5 JP 2021500861A5 JP 2020517377 A JP2020517377 A JP 2020517377A JP 2020517377 A JP2020517377 A JP 2020517377A JP 2021500861 A5 JP2021500861 A5 JP 2021500861A5
Authority
JP
Japan
Prior art keywords
receptor
antigen
cell
cancer
protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2020517377A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021500861A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2018/053247 external-priority patent/WO2019067805A1/en
Publication of JP2021500861A publication Critical patent/JP2021500861A/ja
Publication of JP2021500861A5 publication Critical patent/JP2021500861A5/ja
Priority to JP2023120385A priority Critical patent/JP2023145589A/ja
Pending legal-status Critical Current

Links

JP2020517377A 2017-09-27 2018-09-27 共刺激のための新規のプラットフォーム、新規のcar設計、および養子細胞療法のための他の増強 Pending JP2021500861A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023120385A JP2023145589A (ja) 2017-09-27 2023-07-25 共刺激のための新規のプラットフォーム、新規のcar設計、および養子細胞療法のための他の増強

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762564249P 2017-09-27 2017-09-27
US62/564,249 2017-09-27
PCT/US2018/053247 WO2019067805A1 (en) 2017-09-27 2018-09-27 NEW PLATFORMS FOR CO-STIMULATION, NEW CAR DESIGNS AND OTHER IMPROVEMENTS FOR ADOPTIVE CELL THERAPY

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023120385A Division JP2023145589A (ja) 2017-09-27 2023-07-25 共刺激のための新規のプラットフォーム、新規のcar設計、および養子細胞療法のための他の増強

Publications (2)

Publication Number Publication Date
JP2021500861A JP2021500861A (ja) 2021-01-14
JP2021500861A5 true JP2021500861A5 (https=) 2021-11-04

Family

ID=65902679

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020517377A Pending JP2021500861A (ja) 2017-09-27 2018-09-27 共刺激のための新規のプラットフォーム、新規のcar設計、および養子細胞療法のための他の増強
JP2023120385A Pending JP2023145589A (ja) 2017-09-27 2023-07-25 共刺激のための新規のプラットフォーム、新規のcar設計、および養子細胞療法のための他の増強

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023120385A Pending JP2023145589A (ja) 2017-09-27 2023-07-25 共刺激のための新規のプラットフォーム、新規のcar設計、および養子細胞療法のための他の増強

Country Status (14)

Country Link
US (1) US12570711B2 (https=)
EP (1) EP3687553A4 (https=)
JP (2) JP2021500861A (https=)
KR (1) KR20200071079A (https=)
CN (1) CN111629734A (https=)
AU (2) AU2018338647B2 (https=)
BR (1) BR112020005938A2 (https=)
CA (1) CA3075806A1 (https=)
EA (1) EA202090839A1 (https=)
IL (1) IL273201B2 (https=)
MX (1) MX2020004185A (https=)
SG (1) SG11202002321YA (https=)
WO (1) WO2019067805A1 (https=)
ZA (2) ZA202002046B (https=)

Families Citing this family (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4400516A1 (en) 2014-12-15 2024-07-17 The Regents of the University of California Bispecific or-gate chimeric antigen receptor responsive to cd19 and cd20
EP3234120B1 (en) 2014-12-15 2025-09-03 The Regents of the University of California Cytotoxic molecules responsive to intracellular ligands for selective t cell mediated killing
CN107995913B (zh) 2015-05-18 2022-02-11 T细胞受体治疗公司 使用融合蛋白对tcr重编程的组合物和方法
DK3368571T5 (da) 2015-10-30 2024-09-30 Univ California Transformerende, vækstfaktor-beta-responsive polypeptider og fremgangsmåder til anvendelse deraf
US20200172601A1 (en) 2017-06-22 2020-06-04 University Of Maryland, Baltimore Broadly neutralizing antibodies against hiv
AU2018308088B2 (en) 2017-07-25 2025-05-29 Truebinding, Inc. Treating cancer by blocking the interaction of TIM-3 and its ligand
BR112020006643A2 (pt) * 2017-10-03 2020-09-24 Juno Therapeutics Inc moléculas de ligação específica ao hpv
EP3737692A4 (en) 2018-01-09 2021-09-29 Elstar Therapeutics, Inc. CALRETICULIN AND MODIFIED T-LYMPHOCYTES BINDING CONSTRUCTIONS FOR THE TREATMENT OF DISEASES
WO2019173801A1 (en) * 2018-03-09 2019-09-12 Atreca, Inc. Nucleic acids encoding anti-hiv antibodies
MX2020012927A (es) 2018-06-01 2021-03-25 Univ Southern California Diversos dominios de enlace de antigenos, nuevas plataformas y otras mejoras para terapia celular.
EP3818083A2 (en) 2018-07-03 2021-05-12 Elstar Therapeutics, Inc. Anti-tcr antibody molecules and uses thereof
WO2020095248A1 (en) * 2018-11-07 2020-05-14 Crispr Therapeutics Ag Anti-ptk7 immune cell cancer therapy
AU2020214796A1 (en) 2019-01-30 2021-07-29 Truebinding, Inc. Anti-Gal3 antibodies and uses thereof
US12419913B2 (en) 2019-02-08 2025-09-23 Dna Twopointo, Inc. Modification of CAR-T cells
AU2020224681A1 (en) 2019-02-21 2021-09-16 Marengo Therapeutics, Inc. Antibody molecules that bind to NKp30 and uses thereof
JP7710373B2 (ja) 2019-02-21 2025-07-18 マレンゴ・セラピューティクス,インコーポレーテッド T細胞関連のがん細胞に結合する多機能性分子およびその使用
CA3132202A1 (en) * 2019-04-08 2020-10-15 Phanes Therapeutics, Inc. Humanized anti-dll3 chimeric antigen receptors and uses thereof
EP3962519A1 (en) 2019-05-01 2022-03-09 Juno Therapeutics, Inc. Cells expressing a chimeric receptor from a modified cd247 locus, related polynucleotides and methods
JP7562103B2 (ja) * 2019-05-31 2024-10-07 国立大学法人信州大学 Alkを標的とするキメラ抗原受容体発現細胞
CA3146019A1 (en) 2019-07-17 2021-01-21 Nanjing Legend Biotech Co., Ltd. Anti-dll3 chimeric antigen receptors and uses thereof
US12606612B2 (en) 2019-07-31 2026-04-21 The Wistar Institute Of Anatomy And Biology Multivalent DNA antibody constructs and use thereof
WO2021035170A1 (en) * 2019-08-21 2021-02-25 Precision Biosciences, Inc. Compositions and methods for tcr reprogramming using fusion proteins
JP7748935B2 (ja) * 2019-08-27 2025-10-03 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア IL13Rα2陽性ヒト腫瘍およびイヌ腫瘍を処置するための合成CAR
WO2021046205A1 (en) * 2019-09-04 2021-03-11 Tmunity Therapeutics Inc. Adoptive cell therapy and methods of dosing thereof
EP4025598A1 (en) * 2019-09-06 2022-07-13 Eli Lilly and Company Proteins comprising t-cell receptor constant domains
CN110483621A (zh) * 2019-09-19 2019-11-22 河南省农业科学院 天然免疫库筛选识别环丙沙星单链抗体的核心序列及应用
WO2021062313A1 (en) * 2019-09-26 2021-04-01 Board Of Regents, The University Of Texas System Immunogenic egfr peptide compositions and their use in the treatment of cancer
EP3808765A1 (en) * 2019-10-14 2021-04-21 ETH Zurich Cell line for tcr discovery and engineering and methods of use thereof
CN110903401A (zh) * 2019-11-20 2020-03-24 浙江大学 一种靶向cd19的二代嵌合抗原受体及其表达载体与应用
EP4077398A4 (en) * 2019-12-16 2024-04-10 Legend Biotech Ireland Limited SINGLE DOMAIN ANTIBODIES AND CHIMERIC ANTIGEN RECEPTORS TARGETTING BCMA AND METHODS OF USE THEREOF
CN116234829A (zh) 2020-01-03 2023-06-06 马伦戈治疗公司 抗tcr抗体分子及其用途
IL295074A (en) * 2020-02-04 2022-09-01 Seattle Childrens Hospital Dba Seattle Childrens Res Inst Methods and compositions for stimulation of t cells with a chimeric receptor receptor by hapten-labeled cells
JP7735291B2 (ja) 2020-02-21 2025-09-08 エーアールエス ファーマシューティカルズ、インコーポレイテッド ネクチン-4抗体コンジュゲートおよびその使用
CA3174575A1 (en) 2020-03-02 2021-09-10 The Regents Of The University Of California Chimeric antigen receptors and related methods and compositions for the treatment of cancer
WO2021188454A1 (en) * 2020-03-16 2021-09-23 Marengo Therapeutics, Inc. Engineered cell compositions and methods of use thereof
JP2023518049A (ja) 2020-03-16 2023-04-27 ユニバーシティ オブ サザン カリフォルニア 新規な抗原結合ドメインおよびそれを組み込んだ合成抗原受容体
GB202004371D0 (en) * 2020-03-26 2020-05-13 Glaxosmithkline Ip Dev Ltd CAR constructs
US20240252641A1 (en) * 2020-05-05 2024-08-01 TCR2 Therapeutics Inc. Compositions and methods for tcr reprogramming using cd70 specific fusion proteins
WO2021242776A2 (en) 2020-05-26 2021-12-02 Truebinding, Inc. Methods of treating inflammatory diseases by blocking galectin-3
CA3196549A1 (en) * 2020-11-04 2022-05-12 Bahram Valamehr Engineered ipsc and immune effector cells for heterogenous tumor control
US11661459B2 (en) 2020-12-03 2023-05-30 Century Therapeutics, Inc. Artificial cell death polypeptide for chimeric antigen receptor and uses thereof
AU2021392032A1 (en) 2020-12-03 2023-06-22 Century Therapeutics, Inc. Genetically engineered cells and uses thereof
WO2022122709A1 (en) * 2020-12-07 2022-06-16 Sotio Biotech A.S. Antibody-drug conjugates based on humanized cldn18.2 antibodies
CN112500497B (zh) * 2020-12-14 2021-06-08 南京凯地医疗技术有限公司 Cltx-nkg2d双特异性嵌合抗原受体细胞及其制备方法和应用
AR124414A1 (es) 2020-12-18 2023-03-22 Century Therapeutics Inc Sistema de receptor de antígeno quimérico con especificidad de receptor adaptable
WO2023019144A1 (en) * 2021-08-10 2023-02-16 The Regents Of The University Of California Hla-a2-specific regulatory t cells
US12576135B2 (en) * 2021-09-29 2026-03-17 Chimera Bioengineering, Inc. Compositions and methods for anti-TnMUC1 gold CAR t-cells
CN115881221B (zh) * 2021-09-29 2025-12-16 上海市免疫学研究所 一种冠状病毒转录组鉴定分析方法及分析系统
CN116102658B (zh) * 2021-11-09 2025-04-29 四川大学华西医院 基于gas6构建的嵌合抗原受体免疫细胞制备及其应用
KR102739632B1 (ko) 2022-02-09 2024-12-05 한림대학교 산학협력단 항-cd20 키메릭 항원 수용체를 유효성분으로 포함하는 암의 예방 또는 치료용 약학적 조성물 및 이의 제조 방법
WO2023192992A2 (en) * 2022-03-31 2023-10-05 The Wistar Institute Of Anatomy And Biology Bispecific natural killer engagers that target siglec-7
CN116058334B (zh) * 2022-11-21 2023-08-08 中国人民解放军军事科学院军事医学研究院 一种可视化gvhd动物模型的构建方法及其应用
CN115558021B (zh) * 2022-12-01 2023-03-17 山东大学 一种转录因子、重组细胞及其在制备肿瘤治疗药物的应用
WO2024226829A2 (en) * 2023-04-26 2024-10-31 Yale University Enpp3-binding molecules, compositions formed therefrom, and methods of use thereof for the treatment of cancer
CN116445402B (zh) * 2023-05-09 2025-04-25 中国科学院生态环境研究中心 红系祖细胞的扩增培养基、扩增培养方法及应用
TW202521564A (zh) * 2023-08-14 2025-06-01 美商英特利亞醫療公司 用於基於細胞之療法的cd70 car-t組合物及方法
WO2025084880A1 (ko) * 2023-10-20 2025-04-24 주식회사 이온셀 Ct83 항원에 결합하는 car-t 세포 및 이의 용도
WO2025149667A1 (en) 2024-01-12 2025-07-17 Pheon Therapeutics Ltd Antibody drug conjugates and uses thereof
CN118620059B (zh) * 2024-02-21 2025-08-15 北京永泰瑞科生物科技有限公司 一种t细胞抗原受体及其制备方法和其应用
CN118130793B (zh) * 2024-02-26 2025-07-29 赣南医科大学 视网膜母细胞瘤的生物标志物cdk12及其应用
WO2025215183A1 (en) * 2024-04-11 2025-10-16 Universität Heidelberg Anti-cll1 binding agents
WO2025255267A1 (en) * 2024-06-05 2025-12-11 Dynamic Cell Therapies, Inc. Engineered receptors for activation of regulatory t-cells
CN119823962A (zh) * 2025-01-08 2025-04-15 浙江大学 一种cnb突变体及其应用

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4708871A (en) 1983-03-08 1987-11-24 Commonwealth Serum Laboratories Commission Antigenically active amino acid sequences
US6352694B1 (en) 1994-06-03 2002-03-05 Genetics Institute, Inc. Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells
US6534055B1 (en) 1988-11-23 2003-03-18 Genetics Institute, Inc. Methods for selectively stimulating proliferation of T cells
US6905680B2 (en) 1988-11-23 2005-06-14 Genetics Institute, Inc. Methods of treating HIV infected subjects
US5858358A (en) 1992-04-07 1999-01-12 The United States Of America As Represented By The Secretary Of The Navy Methods for selectively stimulating proliferation of T cells
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5585362A (en) 1989-08-22 1996-12-17 The Regents Of The University Of Michigan Adenovirus vectors for gene therapy
US5199942A (en) 1991-06-07 1993-04-06 Immunex Corporation Method for improving autologous transplantation
IL104570A0 (en) 1992-03-18 1993-05-13 Yeda Res & Dev Chimeric genes and cells transformed therewith
US8211422B2 (en) 1992-03-18 2012-07-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Chimeric receptor genes and cells transformed therewith
US5350674A (en) 1992-09-04 1994-09-27 Becton, Dickinson And Company Intrinsic factor - horse peroxidase conjugates and a method for increasing the stability thereof
US7175843B2 (en) 1994-06-03 2007-02-13 Genetics Institute, Llc Methods for selectively stimulating proliferation of T cells
US7067318B2 (en) 1995-06-07 2006-06-27 The Regents Of The University Of Michigan Methods for transfecting T cells
US6692964B1 (en) 1995-05-04 2004-02-17 The United States Of America As Represented By The Secretary Of The Navy Methods for transfecting T cells
EP1958962A3 (en) 1997-06-12 2013-05-01 Novartis International Pharmaceutical Ltd. Artificial antibody polypeptides
CA2386270A1 (en) 1999-10-15 2001-04-26 University Of Massachusetts Rna interference pathway genes as tools for targeted genetic interference
US6326193B1 (en) 1999-11-05 2001-12-04 Cambria Biosciences, Llc Insect control agent
US6797514B2 (en) 2000-02-24 2004-09-28 Xcyte Therapies, Inc. Simultaneous stimulation and concentration of cells
CA2406864A1 (en) 2000-02-24 2001-08-30 Life Technologies Corporation Simultaneous stimulation and concentration of cells
US7572631B2 (en) 2000-02-24 2009-08-11 Invitrogen Corporation Activation and expansion of T cells
US6867041B2 (en) 2000-02-24 2005-03-15 Xcyte Therapies, Inc. Simultaneous stimulation and concentration of cells
AU2001275474A1 (en) 2000-06-12 2001-12-24 Akkadix Corporation Materials and methods for the control of nematodes
CA2666667C (en) 2006-10-19 2023-06-20 Baylor College Of Medicine Generating an immune response by inducing cd40 and pattern recognition receptors
EP2331680B1 (en) 2008-09-22 2017-05-03 Baylor College Of Medicine Methods and compositions for generating an immune response by inducing cd40 and pattern recognition receptor adapters
WO2011059836A2 (en) 2009-10-29 2011-05-19 Trustees Of Dartmouth College T cell receptor-deficient t cell compositions
WO2011060076A1 (en) 2009-11-10 2011-05-19 Amgen Inc. Anti-c-mpl antibodies
AU2011239569B2 (en) 2010-04-16 2014-07-24 Baylor College Of Medicine Method for treating solid tumors
EP2694549B1 (en) 2011-04-08 2018-08-15 The United States of America, as represented by The Secretary, Department of Health and Human Services Anti-epidermal growth factor receptor variant iii chimeric antigen receptors and use of same for the treatment of cancer
CN107058101B (zh) 2011-10-17 2021-06-01 麻省理工学院 细胞内传递
HRP20201595T1 (hr) 2011-11-28 2020-12-11 Merck Patent Gmbh Anti-pd-l1 protutijela i njihova uporaba
WO2014160030A2 (en) 2013-03-13 2014-10-02 Health Research, Inc. Compositions and methods for use of recombinant t cell receptors for direct recognition of tumor antigen
JP6346266B2 (ja) * 2013-03-21 2018-06-20 サンガモ セラピューティクス, インコーポレイテッド 操作されたジンクフィンガータンパク質ヌクレアーゼを使用するt細胞受容体遺伝子の標的化された破壊
WO2015107545A1 (en) 2013-12-18 2015-07-23 Dharmesh Mahendrabhai Shah Water soluble salts of dasatinib hydrate
CN106459990B (zh) 2014-02-07 2021-06-01 麦克马斯特大学 三功能t细胞抗原偶联物及其制备方法和用途
US10934346B2 (en) * 2014-02-14 2021-03-02 Bellicum Pharmaceuticals, Inc. Modified T cell comprising a polynucleotide encoding an inducible stimulating molecule comprising MyD88, CD40 and FKBP12
EP3593812A3 (en) 2014-03-15 2020-05-27 Novartis AG Treatment of cancer using chimeric antigen receptor
ES2869972T3 (es) * 2015-01-26 2021-10-26 Cellectis Sistemas de receptores de antígenos quiméricos dirigidos por mAb para clasificar/agotar células inmunitarias genomanipuladas
JP6960855B2 (ja) 2015-03-20 2021-11-05 ジョージア ステート ユニバーシティ リサーチ ファウンデーション, インク.Georgia State University Research Foundation, Inc. Copd及びその他の炎症状態を治療するための組成物及び方法
CN107995913B (zh) 2015-05-18 2022-02-11 T细胞受体治疗公司 使用融合蛋白对tcr重编程的组合物和方法
EP3322801A1 (en) * 2015-07-15 2018-05-23 Juno Therapeutics, Inc. Engineered cells for adoptive cell therapy
EP3842450A1 (en) * 2015-10-23 2021-06-30 Eureka Therapeutics, Inc. Antibody/t-cell receptor chimeric constructs and uses thereof
WO2017076308A1 (zh) * 2015-11-04 2017-05-11 广州市香雪制药股份有限公司 识别ny-eso-1抗原短肽的tcr
CN105647871A (zh) * 2016-01-27 2016-06-08 苏州佰通生物科技有限公司 一种可异体移植的嵌合抗原受体t细胞及制备方法
WO2017172981A2 (en) 2016-03-29 2017-10-05 University Of Southern California Chimeric antigen receptors targeting cancer
CA3018253A1 (en) 2016-03-31 2017-10-05 University Of Southern California A highly sensitive and specific luciferase based reporter assay for antigen detection
US11377637B2 (en) * 2016-04-15 2022-07-05 Memorial Sloan Kettering Cancer Center Transgenic T cell and chimeric antigen receptor T cell compositions and related methods
WO2017192536A1 (en) * 2016-05-02 2017-11-09 University Of Kansas Eliminating mhc restriction from the t cell receptor as a strategy for immunotherapy
US11377875B2 (en) 2016-09-19 2022-07-05 Level Home, Inc. Deadbolt position sensing
CN110352068A (zh) 2016-12-02 2019-10-18 南加利福尼亚大学 合成的免疫受体及其使用方法
MX2020012927A (es) 2018-06-01 2021-03-25 Univ Southern California Diversos dominios de enlace de antigenos, nuevas plataformas y otras mejoras para terapia celular.
WO2020028444A1 (en) * 2018-07-30 2020-02-06 University Of Southern California Improving the efficacy and safety of adoptive cellular therapies

Similar Documents

Publication Publication Date Title
JP2021500861A5 (https=)
IL273201B1 (en) Novel platforms for co-stimulation, novel car designs and other enhancements for adoptive cellular therapy
JP2021525509A5 (https=)
JP2020500530A5 (https=)
JP7487112B2 (ja) Cd19指向性キメラ抗原受容体および免疫療法におけるその使用
JPWO2019232503A5 (https=)
US20240390496A1 (en) Single-chain and multi-chain synthetic antigen receptors for diverse immune cells
JPWO2021188599A5 (https=)
AU2021307614B2 (en) Engineered immune cell for allotransplantation
JP2025037871A5 (https=)
US20230028399A1 (en) Bcma-directed cellular immunotherapy compositions and methods
AU2025203096A1 (en) Engineered immune cell expressing NK inhibitory molecule and use thereof
JP2020517263A5 (https=)
CN114015656A (zh) 用于同种异体移植的工程化免疫细胞
JPWO2022178367A5 (https=)
RU2018122106A (ru) Буферы для стабилизации лентивирусных препаратов
US20250319185A1 (en) Bcma-directed cellular immunotherapy compositions and methods
WO2021030153A2 (en) Engineered t cell receptors and uses thereof
JP2023518293A (ja) 新規の組換え細胞表面マーカー
JP2025520124A (ja) キメラアダプターポリペプチドを含む組成物及び方法
CN117202921A (zh) 用于多种免疫细胞的单链和多链合成抗原受体
WO2022267983A1 (zh) 工程化免疫细胞及其用途
JPWO2022241036A5 (https=)
JPWO2021231505A5 (https=)
RU2842294C1 (ru) Химерные цитокиновые рецепторы, содержащие домены, связывающие tgf-бета